Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

Ipca Laboratories Ltd. Interim / Quarterly Report 2021

Feb 4, 2021

61700_rns_2021-02-04_b88a2fa9-7d80-453f-9a03-cbd5d9ecad5a.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

I

~~IJ2fo~

THRU ONLINE FILING

February 4, 2021

BSE Ltd. Phiroze Jeejeebhoy Towers Dalal Street Mumbai 400 023 Scrip Code: 524494

National Stock Exchange India Limited, Exchange Plaza, C-1, Block-G, Bandra Kurla Complex, Bandra - (East). Mumbai-400051. Scrip Code: IPCALAB

Dear Sirs,

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith our Standalone and Consolidated Unaudited Financial Results along with limited review report of the Company's Auditors for the 3[rd] Quarter and nine months ended 31st December, 2021, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

We are also enclosing herewith a press release issued by the Company in respect of its Q3 FY21 /9 months FY21 unaudited financial Results.

Kindly note that the Board meeting started at 11.30 a.m. and concluded at 12.50 p.m.

Thanking you

Yours faithfully For Ipca Laboratories Limited ~ - . .

Harish P. Kamath Corporate Counsel & Company Secretary

Ipea Laboratories Ltd. www.ipea.eom

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2262105000 F:+91 2262105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 E: [email protected] ClN: L24239MH 1949PLC00783 7

Ipea Laboratories limited

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN : L24239MH1949PLC007837

Tel:+91 2266474444, E-mail: [email protected] Website: www.ipca.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

==> picture [546 x 564] intentionally omitted <==

----- Start of picture text -----

(~ Crores)
Sr. No. Particulars Quarter Ended Nine Months Ended Year Ended
Dec 31, 2020 Sept 30, 2020 Dec 31, 2019 Dec 31, 2020 Dec 31, 2019 Mar31,2020
Unaudited Unaudited Unaudited Unaudited Unaudited Audited
I Revenue from operalions 1315.22 1297.77 1139.07 4098.24 3362.64 4367.43
II Other Income 15.65 15.00 17.63 42.33 51.39 64.69
III Total Income (1+11) 1330.87 1312.77 1156.70 4140.57 3414.03 4432.12
IV Expenses:
a) Cost of malerials consumed 377.72 405.78 350.63 1146.23 1060.04 1431.10
b) Purchases of stock-in-trade 61.60 32.78 53.98 127.75 153.80 204.65
c) Changes in inventories of finished goods, 28.08 (32.00) (23.08) 7.42 (60.08) (155.05)
work-in-progress and stock-in-trade
d) Employee benefits expense 230.03 239.09 217.72 711.04 642.91 870.79
e) Finance costs 1.56 1.81 3.80 5.83 12.32 15.79
f) Depreciation and amortisation expense 47.66 46.26 46.16 139.15 133.31 178.69
g) Other expenses 268.96 291.96 274.38 808.86 843.93 1101.18
Total Expenses (IV) 1015.61 985.68 923.59 2946.28 2786.23 3647.15
V Profit before exceptional items and tax (III-IV) 315.26 327.09 233.11 1194.29 627.80 784.97
VI Exceptional ilems - - . -
VII Profit before tax (V-VI) 315.26 327.09 233.11 1194.29 627.80 784.97
VIII Tax Expense
- Current tax 55.10 52.10 40.78 208.70 109.80 137.98
- Short / (Excess) provision of earlier years - - -
- Deferred tax liability / (asset) including MAT credil 0.19 (0.69) (4.30) (3.70) (6.70) (5.47)
IX Profit for the period from continuing operations (VII-VIII) 259.97 275.68 196.63 989.29 524.70 652.46
X Other Comprehensive Income
A (i) Items that will not be reclassified to profit or loss -
- Acluarial gain/(Ioss) 0.59 (0.45) (0.61) (1.17) (4.57) (7.21)
(ii) Income tax relating 10ilems thai will not be reclassified (0.10) 0.08 0.11 0.21 0.80 1.25
10profit or loss
B (i) Items that will be reclassified to profit or loss
- Exchange difference in lranslaling lhe financial stalemenl of (0.19) (0.12) 0.23 (0.18) 0.02 (0.60)
foreign operation
- Gain/(Ioss) on cash flow hedge 0.30 0.18 0.12 0.51 (0.71) (1.47)
(ii) Income tax relating to items that will be reclassified to (0.02) (0.01) (0.04) (0.06) 0.12 0.36
profit or loss
Other Comprehensive Income / (Loss) for the period net of tax (X) 0.58 (0.32) (0.19) (0.69) (4.34) (7.67)
XI Total Comprehensive Income for the period (IX+X) 260.55 275.36 196.44 988.60 520.36 644.79
XII Paid-up equity share capilal (Face value of 'I' 2/- each) 25.37 25.37 25.27 25.37 25.27 25.27
XIII Olher Equity - - - - - 3640.33
XIV Share Warranl - - - - - 11.94
XV NelWorth - - - - - 3677.54
XVI Earnings per share (of ~ 21- each) (Not annualised):
Basic ( f) 20.49 21.79 15.56 78.16 41.53 51.64
Diluted ('1') 20.49 21.79 15.56 78.16 41.51 51.60
----- End of picture text -----

: 2:

Notes:

  • 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 4, 2021.The Statutory Auditors have carried out the limited review of the results.

  • 2 The Company has only one operating segment viz. 'Pharmaceuticals'.

  • 3 Figures of the previous periods have been regrouped wherever necessary.

==> picture [269 x 83] intentionally omitted <==

----- Start of picture text -----

Place: Mumbai,
Date : February4, 2021
SIGNED FOR IDENTIFICATION
BY~
-
G. M. KAPADIA & CO.
MUMBAI.
----- End of picture text -----

==> picture [108 x 88] intentionally omitted <==

----- Start of picture text -----

By Orderof the Board
For Ipea Laboratories limited
Chairman & ManagingDirector
(DIN 00012691)
----- End of picture text -----

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

G. M. KAPADIA & co. (REGISTERED)

CHARTERED ACCOUNTANTS

PHONE:(91-22) 6611 6611 FAX: (91-22) 66116600

Independent Auditor's Limited Review Report on unaudited standalone financial results of Ipca Laboratories Limited for the quarter and nine months ended on December 31, 2020 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To

The Board of Directors

Ipca Laboratories Limited Mumbai

  1. We have reviewed the accompanying statement of unaudited standalone financial results ("the Statement") of Ipca Laboratories Limited ("the Company") for the quarter and nine months ended on December 31, 2020, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

  2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 'Interim Financial Reporting' ("Ind AS 34") prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

  3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

  4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement, prepared in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed

MUMBAI NEW DELHI CHENNAI BENGALURU HYDERABAD JAIPUR

G. M. KAPADIA & CO.

the information required to be disclosed in terms of Regulation 33 of the Listing Regulations as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Mumbai Dated: February 04, 2021

For G. M. KAPADIA & CO. Chartered Accountants Firm R~egistrationNo. 104767W Atu) Shah Partner Membership No. 039569 : 21039569AAAACD6868

Ipea Laboratories Limited

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (W), Mumbai 400 067

CIN: L24239MHI949PLC007837

Tel:+91 2266474444, E.mail : [email protected] Website: www.ipca.com STATEMENT OF CONSOUDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2020

Tel:+91 2266474444,
E.mail :[email protected]
Website:
www.ipca.com		 Tel:+91 2266474444,
E.mail :[email protected]
Website:
www.ipca.com		 Tel:+91 2266474444,
E.mail :[email protected]
Website:
www.ipca.com		 Tel:+91 2266474444,
E.mail :[email protected]
Website:
www.ipca.com		 Tel:+91 2266474444,
E.mail :[email protected]
Website:
www.ipca.com		 Tel:+91 2266474444,
E.mail :[email protected]
Website:
www.ipca.com


STATEMENT
OF CONSOUDATED
UNAUDITED
FINANCIAL
RESULTS
FOR THE QUARTER
AND NINE MONTHS
ENDED
DECEMBER
31, 2020
Sr. No .
Particulars		 (~Croresl
hs
Ended
VearEnded
Dec 31, 2019
March 31, 2020
Unaudited
Audited
3574.95
4648.71
53.27
67.00
3628.22
4715.71
1082.69
1460.37
274.37
359.88
(77.52)
(176.12)
679.05
921.23
12.83
16.50
146.56
210.50
878.12
1176.65
2996.10
3969.01
632.12
746.70
(5.48)
(7.81)
626.64
738.89
-
626.64
738.89
111.68
140.59
0.19
0.52
(5.74)
(5.78)
520.51
603.56
(4.57)
(7.40)
0.80
t.30
7.17
11.10
(0.71)
(t.47)
0.12
0.36
(0.37)
(0.36)
2.44
3.53
522.95
607.09
520.31
606.32
0.20
(2.76)
520.51
603.56
2.04
2.68
0.40
0.85
2.44
3.53
522.35
609.00
0.60
(1.91)
522.95
607.09
25.27
25.27
3590.27
11.94
3627.46
41.20
47.77
Quarter
Ended
Dec 31, 2020
Sept 30, 202~		 Dec 31, 2019 Nine
mont
Dec 31, 2020
I
II
III
IV
V
VI
VII
VIII
IX
X
XI
XII
XIII
XIV
XV
XVI
XVII
XVIII		 Revenue from operations Unaudited
Unaudited
1409.83
1361.10		 Unaudited
1212.86		 Unaudited
4305.33
Other Income 15.38
15.45		 18.13 42.92
Total Income
(1+11)
Expenses:
a) Cost of materials consumed
b) Purchases of stock-in-trade
c) Changes in inventories of finished goods,
work-In-progress and stock-In-trade
d) Employee benefits expense
e) Finance costs
f) Depreciation and amortisation expense		 1425.21
1376.55
393.51
414.07
97.64
57.94
24.24
(29.33)
245.07
254.54
2.29
2.31
53.52
52.12		 1230.99
359.92
96.68
(32.79)
231.30
4.01
50.83		 4348.25
1179.58
223.51
(13.38)
755.94
7.34
156.67
g) Other expenses 282.44
30369		 284.09 844.24
.
Total Expenses
(IV)
Profit from ordinary
activity
before share of profit of associates
&joint
venture,
exceptional
Items
& tax (III • IV)
Share of Profit_I_(loss) of associates & joint venture accounted by using the
equity method
Profit before exceptional
Items and tax (V+VI)
Exceptional items
Profit before
tax (VII - VIII)
Tax Expense
• Current tax
• Short I(Excess) provision of earlier years		 1098.71
1055.34
326.50
321.21		 994.04
236.95		 3153.90
1194.35
(2.2t)
(1.92)
324.29
319.29		 (2.52)
234.43		 (5.20)
1189.15
324.29
3t9.29
56.61
53.34
(0.01)		 234.43
40.95		 1189.15
212.93
(0.01)
- Deferred tax liability / (asset)
including MAT credit		 0.12
(0.74)		 (4.06) (3.71)
Profit for the period
from conlinulng
operations
(IX-X)
Other Comprehensive
Income
A. (i) Items that will not be reclassified to profit or loss -
• Actuarial gain/(Ioss)
(ii) Income tax relating to items thai will not be reclassified
to profit or loss
8. (i) Items that will be reclassified to profit or loss
- Exchange difference in translating the financial statement of foreign
operation
- Gain/(Ioss)
on cash flow hedge
(ii) Income tax relating 10items that will be reclassified to
profit or loss		 267.56
266.70
0.59
(0.45)
(0.10)
0.08
t.23
(0.31)
0.30
0.18
(0.02)
(0.01)		 197.54
(0.61)
0.11
4.06
0.12
(0.04)		 979.94
(l.t7)
0.21
(1.12)
0.51
(0.06)
C. Share ofoel from investment in associates (0.t3)
Other Comprehensive
Income I (Loss) for the period, net of tax		 2.00
(0.51)		 3.51 (1.63)
Total Comprehensive
Income for the period (XI +XII)
Profit for the period attributable
to :
Owners of the parent
Non-controlling
interest - profit / (loss)
Other Comprehensive
Income for the period attributable
to :
Owners of the parent
Non-controlling interest - profit / (loss)
Total Comprehensive
Income for the period attributable
to :
Owners of the parent
Non-controlling interest.
profit / (loss)
Paid-up equity share capital (Face value of ~ 2/- each)
Other Equity
Share Warrant
Net Worth
Earning per equity share ( off 2/- each) (Not annualised):
Basic (~)		 269.56
266.19
265.47
267.07		 201.05
197.61		 978.31
978.67
2.09
(0.37)		 (0.07) 1.27
267.56
266.70
2.09
(0.38)		 197.54
3.43		 979.94
(t.42)
(0.09)
(0.13)		 0.08 (0.2t)
2.00
(0.51)
267.56
266.69		 3.51
201.04		 (1.63)
977.25
2.00
(0.50)		 0.01 t.06
269.56
266.19
25.37
25.37
.
2t.09
21.08		 201.05
25.27
-
t5.63		 978.31
25.37
.
77.42
Diluted (~) 21.09
21.08		 15.63 77.42 41.18
47.73
4;0~St./.
c...,'b.
-.. ..•..~
o~
.\~
-Q')
@
as
"'~i,j ':~i
0-
....• ~~'
~~ -;#--
'I _ •.-/

: 2:

Notes:

  • 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on February 4, 2021.The Statutory Auditors have carried out the limited review of the results.

  • 2 The Group has only one operating segment viz. 'Pharmaceuticals'.

  • 3 Figures of the previous periods have been regrouped wherever necessary.

==> picture [254 x 77] intentionally omitted <==

----- Start of picture text -----

Place: Mumbai,
Date : February4, 2021
SIGNED FOR IDENTIFICATIO~
BY
~
G. M. KAPADIA & CO.
MUMBAI.
----- End of picture text -----

==> picture [97 x 25] intentionally omitted <==

----- Start of picture text -----

Pre chand Godha
Chairman & Managing Director
(DIN 00012691)
----- End of picture text -----

CHARTERED ACCOUNTANTS

G. M. KAPADIA & co. (REGISTERED)

1007, RAHEJA CHAMBERS, 213, NARIMAN POINT, MUMBAI 400 021. INDIA

PHONE: (91-22) 6611 6611 FAX: (91-22) 6611 6600

Independent Auditor's Limited Review Report on unaudited consolidated financial results for the quarter and nine months ended on December 31, 2020 of Ipca Laboratories Limited pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To,

The Board of Directors Ipca Laboratories Limited Mumbai

  1. We have reviewed the accompanying statement of unaudited consolidated financial results ("the Statement") ofIpca Laboratories Limited ( "the Parent") and its subsidiaries, (the Parent and its subsidiaries together referred to as the Group) and its share of the net profit/(loss) after tax and total comprehensive income / (loss) of its joint venture and associates for the quarter and nine months ended December 31, 2020, (the Statement) being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").

  2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

  3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

MUMBAI NEW DELHI CHENNAI BENGALURU HYDERABAD JAIPUR

G. M. KAPADIA & C o.

4. The Statement includes the unaudited standalone financial results ofthe following entities:

Sr. No. me of the Entities
Na
bsidiaries
Su
1 a Pharma Nigeria Limited, Nigeria
Ipc
2 a Pharmaceuticals
Limited, SA. de CV, Mexico
Ipc
3 Ipca Laboratories
(U.K.) Limited, UK
4 Ipca Pharmaceuticals
Inc. USA
5 Ipca Pharma (Australia) Pty Limited, Australia
6 Tonira Exports Limited, India
7 Ramdev Chemicals
Private Limited, India
Step down Subsidiaries
8 Onyx Scientific Limited, UK
9 Ipca Pharma (NZ) Pty Limited, New Zealand
10 Pisgah Labs Inc., USA
11 Bayshore
Pharmaceuticals
LLC, USA
Joint
Venture
12 Avik Pharmaceuticals
Limited, India
Associates
13 Trophic Wellness Private Limited, India
14 Krebs Biochemicals
Industries Limited, India (reviewed		 results)

  1. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review report of the other auditor referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

  2. We did not review the unaudited standalone financial results of one associate included in the Statement in which the Group's share of net loss after tax is Rs. 3.19 crores and 8.44 crores and total comprehensive loss ofRs. 3.19 crores and 8.44 crores for the quarter and nine months ended December 31, 2020, respectively as considered in the Statement. This unaudited standalone financial result of this associate has been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of this associate, is based solely on the report of the other auditor and the procedures performed by us as stated in paragraph 3 above. Our conclusion on the Statement is not modified in respect of the above matter.

G. M. KAPADIA & CO.

  1. The Statement includes the standalone financial results of eleven subsidiaries (including nine foreign subsidiaries) which have not been reviewed / audited by their auditors or by us, whose unaudited standalone financial results reflect total revenues ofRs. 96.07 crores and Rs. 246.88 crores, total net profit after tax ofRs. 8.23 crores and Rs. 1.20 crores, total comprehensive income/(Ioss) of Rs. 10.84 crores and Rs. (2.09) crores, for the quarter ended and nine months ended December 31, 2020, respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax ofRs. 0.52 crores and Rs. 2.81 crores and total comprehensive income ofRs. 0.52 crores and Rs. 2.81 crores for the quarter and nine months ended December 31, 2020, respectively, as considered in the Statement, in respect of one associate and one joint venture, based on their unaudited standalone financial results which have not been reviewed by their auditors or by us. These financial results are certified by the management. Our conclusion on the Statement is not modified in respect of the above matters.

==> picture [75 x 38] intentionally omitted <==

----- Start of picture text -----

~
-
Atul Shah
Partner
----- End of picture text -----

Place: Mumbai Dated: February 04, 2021

PRESS RELEASE

Ipca Laboratories Q3 FY21 Financial Results

Mumbai, February 4, 2021: Ipca Laboratories limited today announced its unaudited financial results for the third quarter and nine months ended 31[51] December, 2020.

Key Financials of Q3 FY21

  • Standalone Net total Income up 15% at Rs.1330.87 crores.

  • Consolidated Net total Income up 16% at Rs.1425.21 crores.

  • Indian formulations income up 8% at Rs.523.16 crores.

  • Exports Income up 21% at Rs.709.25 crores.

  • Standalone EBITDA margin (before forex (gain)/loss) @ 26.98% in Q3 FY21 as against @ 24.46% in Q3 FY20.

  • Consolidated EBITDA margin @ 26.47% in Q3 FY21 as against @ 23.56% in Q3 FY20.

  • Standalone Net Profit at Rs.259.97 crores up 32%.

  • Consolidated Net Profit at Rs.267.56 crores up 35%.

==> picture [433 x 168] intentionally omitted <==

----- Start of picture text -----

Standalone Q3 FY21 at a glance (Rs.Crares)
Particulars Q3 FY21 Q3 FY20 Growth
Net Total Income 1330.87 1156.70 15%
Export Income 709.25 585.61 21%
EBITDAbefore Forex (gain) 1 loss 359.12 282.94 27%
Forex (gain) 1 loss (5.36) (0.13) -
Finance Cost 1.56 3.80 -59%
Depreciation and Amortisation 47.66 46.16 3%
Tax Expense 55.29 36.48 52%
Net Profit after tax 259.97 196.63 32%
Earnings per share of Rs. 2/- each (Rs.) 20.49 15.56 32%
----- End of picture text -----

==> picture [322 x 149] intentionally omitted <==

----- Start of picture text -----

|||||||
|---|---|---|---|---|---|
|Consolidated|Q3|FY21|at|a glance|(Rs.erares)|
|Q3|FY21|Q3|FY20|Growth|
|1425.21|1230.99|16%|
|377.32|290.03|30%|
|2.21|2.52|-12%|
|(4.99)|(1.76) .|
|2.29|4.01|-43%|
|53.52|50.83|5%|
|56.73|36.89|54%|
|267.56|197.54|35%|
|21.09|15.63|35%|

----- End of picture text -----

Ipea Laboratories Ltd. www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2262105000 F:+91 22 6210 5005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 E: [email protected] ClN: L24239MH 1949PLC007837

:2:

==> picture [435 x 299] intentionally omitted <==

----- Start of picture text -----

Q3 FY21 Revenue break-up IRs. Crores)
Particulars Q3 FY21 Q3 FY20 Growth
Formulations
Domestic 523.16 485.63 8%
Exports
Branded 77.50 112.98 -31%
Institutional 138.55 47.82 190%
Generics 215.13 192.63 12%
Total Formulations 954.34 839.06 14%
APls
Domestic 74.00 53.18 39%
Exports 278.07 232.18 20%
Total APls 352.07 285.36 23%
Other Operating Income 8.81 14.65 -40%
Standalone Revenue from Operations 1315.22 1139.07 15%
Revenue from Operations - Subsidiaries 95.78 77.08 24%
Intra-group transactions (1.17) (3.29) -
Consolidated Revenue from Operations 1409.83 1212.86 16%
Other Income 15.38 18.13 -15%
Consolidated Net Total Income 1425.21 1230.99 16%
----- End of picture text -----

Key Financials of 9 months FY21

  • Standalone Net Total Income up 21% at Rs.4140.57 crores.

  • Consolidated Net Total Income up 20% at Rs.4348.25 crores.

  • Indian formulations income up 4% at Rs.1548.06 crores.

  • Exports Income up 31% at Rs.2170.04 crores.

  • Standalone EBITDA margin (before forex (gain) / loss) @ 31.66% in 9 months FY21 as against @ 22.45% in 9 months FY20

  • Consolidated EBITDA margin @ 30.59% in 9 months FY21 as against @ 21.58% in 9 months FY20

  • Standalone Net Profit at Rs.989.29 crores up 89%.

  • Consolidated Net Profit at Rs.979.94 crores up 88%

==> picture [417 x 160] intentionally omitted <==

----- Start of picture text -----

|||||||||
|---|---|---|---|---|---|---|---|
|Standalone|Nine|Months|FY21|at|a glance|IRs.|Crores)|
|Particulars|9|months|9|months|Growth|
|FY21|FY20|
|4140.57|3414.03|21%|
|2170.04|1651.09|I|31%|
|1310.86|766.51|71%|
|(28.41)|(6.92)|
|5.83|12.32|-53%|
|139.15|133.31|4%|
|205.00|103.10|99%|
|989.29|524.70|89%|
|78.16|41.53|88%|

----- End of picture text -----

Ipca Laboratories Ltd. www.ipca.com

. ndustrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 226210 5000 F:+91 2262105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 E: [email protected] ClN: L24239MH 1949PLC007837

:3:

Consolidated
Nine Months
Particulars		 FY21 at a glance
9 months		 9 months (Rs. Crores)
Growth
FY21 FY20
Consolidated
Net Total Income		 4348.25 3628.22 20%
Consolidted
EBITDA before Forex (gain) / loss		 1330.30 782.95 70%
Share of (profit) / loss of associates & joint venture 5.20 5.48 -5%
Forex (gain) / loss (28.06) (8.56) -
Finance Cost 7.34 12.83 -43%
Depreciation and Amortisation 156.67 146.56 7%
Tax Expense 209.21 106.13 97%
Consolidated
Net Profit after tax		 979.94 520.51 88%
Consolidated Earnings per share of Rs.2/- each (Rs.) 77.42 41.20 88%
Nine Months
FY21 Revenue break-up
Particulars
9 months		 9 months (Rs. Crores)
Growth

==> picture [438 x 298] intentionally omitted <==

----- Start of picture text -----

Nine Months FY21 Revenue break-up (Rs. Crores)
Particulars 9 months 9 months Growth
FY21 FY20
Formulations
Domestic 1548.06 1481.65 4%
Exports
Branded 302.41 304.81 -1%
Institutional 309.13 136.60 126%
Generics 647.65 497.67 30%
Total Formulations 2807.25 2420.73 16%
APls
Domestic 335.54 186.05 80%
Exports 910.85 712.01 28%
Total APls 1246.39 898.06 39%
Other Operating Income 44.60 43.85 2%
Standalone Revenue from Operations 4098.24 3362.64 22%
Revenue from Operations - Subsidiaries 245.08 224.62 9%
-
Intra-group transactions (37.99) (12.31)
Consolidated Revenue from Operations 4305.33 3574.95 20%
Other Income 42.92 53.27 -19%
Consolidated Total Income 4348.25 3628.22 20%
----- End of picture text -----

End: Unaudited Standalone Financial Results

Contact Information: Harish P. Kamath, Corporate Counsel & Company Secretary at [email protected] or on +91-22- 6210 6050

Ipca Laboratories Ltd. www.ipca.com

125, Kandivli Industrial Estate, CTS No. 328, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2262105000 F:+9122 62105005 Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India I T: +91 2266474444 E: [email protected] CIN: L24239MH 1949PLC007837

More from Ipca Laboratories Ltd.

Regulatory Filings 2026
Jun 9
Regulatory Filings 2026
Jun 9
Call Transcript 2026
Jun 4
Call Transcript 2026
Jun 4
Regulatory Filings 2026
Jun 1
Report Publication Announcement 2026
Jun 1
Report Publication Announcement 2026
Jun 1
Report Publication Announcement 2026
Jun 1
Regulatory Filings 2026
Jun 1
Regulatory Filings 2026
Jun 1
View all filings →